Myrcludex B
- Generic Name
- Myrcludex B
- Brand Names
- -
- Drug Type
- Biotech
- Chemical Formula
- -
- CAS Number
- 406461-66-3
- Unique Ingredient Identifier
- JA8K50N04H
- Background
Myrcludex B is under investigation in clinical trial NCT03546621 (A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D).
- Associated Conditions
- -
- Associated Therapies
- -
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
- Conditions
- Interventions
- First Posted Date
- 2018-06-06
- Last Posted Date
- 2021-05-10
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03546621
- Locations
- 🇩🇪
Klinik für Gastroenterologie, Hepatologie und Endokrinologie, Medizinische Hochschule Hannover, Hannover, Germany
🇷🇺State Autonomous Healthcare Institution "Republican Clinical Infectious Diseases Hospital named after Prof. A.F. Agafonov "(SAHI RCID), Kazan, Russian Federation
🇷🇺State Budget Health Institution of Moscow "Infectious Clinical Hospital No. 1 of the Moscow Healthcare Department", Moscow, Russian Federation
Myrcludex B in Combination With Peginterferon Alfa-2a Versus Peginterferon Alfa-2a Alone in Patients With Chronic Viral Hepatitis B With Delta-agent
- Conditions
- Interventions
- First Posted Date
- 2016-09-02
- Last Posted Date
- 2021-04-30
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 90
- Registration Number
- NCT02888106
- Locations
- 🇷🇺
LLC "Clinic of Modern Medicine", Moscow, Russian Federation
🇷🇺Medical Company "Gepatolog" LLC, Samara, Russian Federation
🇷🇺State Budgetary Institution of healthcare 'Stavropol regional clinical hospital', Stavropol', Russian Federation
Myrcludex B vs Entecavir in Patients With HBeAg Negative Chronic Hepatitis B
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2018-09-19
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 48
- Registration Number
- NCT02881008
- Locations
- 🇷🇺
FSBI of Higher Education "People's Friendship University", Moscow, Russian Federation
🇷🇺SBIH "Stavropol Regional Clinical Hospital", Stavropol', Russian Federation
🇷🇺1-st MMU n.a. I.M. Sechenov based in Moscow State-Owned Health Care Institution "Infectious Clinical Hospital № 2 of Moscow Healthcare Department", Moscow, Russian Federation
Myrcludex B Plus Pegylated Interferon-alpha-2a in Patients With HBeAg Negative HBV/HDV Co-infection
- Conditions
- Interventions
- First Posted Date
- 2015-12-22
- Last Posted Date
- 2018-04-13
- Lead Sponsor
- Hepatera Ltd.
- Target Recruit Count
- 24
- Registration Number
- NCT02637999
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.